GlassScriptPhysician profile
Rafael L Rocha
NPI 1750380903
$479.51
in general payments reported to CMS, 2019-2025
17 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10.89 · 2020: $237 · 2021: $28.22 · 2023: $38.40 · 2024: $39.49 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $203.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $203.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Foundation Medicine, INC. | $53.27 | 2020 | |
| Astellas Pharma US INC | $47.05 | 2020-2025 | Padcev |
| Daiichi Sankyo INC. | $45.48 | 2020 | |
| Eisai INC. | $39.49 | 2024 | |
| Lilly USA, LLC | $38.95 | 2020-2025 | Verzenio, Jaypirca |
| Janssen Biotech, INC. | $38.40 | 2023 | Imbruvica |
| Gilead Sciences, INC. | $31.68 | 2021-2025 | Trodelvy |
| Jazz Pharmaceuticals INC. | $30.65 | 2019-2020 | |
| Abbvie INC. | $22.37 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $19.86 | 2025 | |
| Siemens Medical Solutions USA, INC. | $19.21 | 2025 | Somatom Go.Top |
| Kite Pharma, INC. | $16.84 | 2020 | |
| Merck Sharp & Dohme LLC | $16.73 | 2020 | |
| Incyte Corporation | $16.49 | 2020 | |
| Puma Biotechnology, INC. | $16.30 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $14.70 | 2020 | |
| Amag Pharmaceuticals, INC. | $12.04 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rafael Rocha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.